Dynavax Technologies (DVAX) Competitors $13.39 -0.13 (-0.96%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DVAX vs. PRTA, RIGL, GTHX, URGN, PBYI, IONS, ALKS, FOLD, GERN, and LGNDShould you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Prothena (PRTA), Rigel Pharmaceuticals (RIGL), G1 Therapeutics (GTHX), UroGen Pharma (URGN), Puma Biotechnology (PBYI), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry. Dynavax Technologies vs. Prothena Rigel Pharmaceuticals G1 Therapeutics UroGen Pharma Puma Biotechnology Ionis Pharmaceuticals Alkermes Amicus Therapeutics Geron Ligand Pharmaceuticals Dynavax Technologies (NASDAQ:DVAX) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation. Which has stronger earnings & valuation, DVAX or PRTA? Dynavax Technologies has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDynavax Technologies$232.28M7.58-$6.39M$0.13103.01Prothena$91.37M9.48-$147.03M-$2.48-6.49 Does the media favor DVAX or PRTA? In the previous week, Dynavax Technologies had 21 more articles in the media than Prothena. MarketBeat recorded 32 mentions for Dynavax Technologies and 11 mentions for Prothena. Dynavax Technologies' average media sentiment score of 0.63 beat Prothena's score of 0.51 indicating that Dynavax Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dynavax Technologies 6 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in DVAX or PRTA? 97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by company insiders. Comparatively, 28.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend DVAX or PRTA? Dynavax Technologies currently has a consensus price target of $22.00, suggesting a potential upside of 64.30%. Prothena has a consensus price target of $61.86, suggesting a potential upside of 284.21%. Given Prothena's stronger consensus rating and higher probable upside, analysts clearly believe Prothena is more favorable than Dynavax Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynavax Technologies 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Prothena 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the MarketBeat Community believe in DVAX or PRTA? Prothena received 134 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 70.51% of users gave Prothena an outperform vote while only 65.87% of users gave Dynavax Technologies an outperform vote. CompanyUnderperformOutperformDynavax TechnologiesOutperform Votes47165.87% Underperform Votes24434.13% ProthenaOutperform Votes60570.51% Underperform Votes25329.49% Which has more risk and volatility, DVAX or PRTA? Dynavax Technologies has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Is DVAX or PRTA more profitable? Dynavax Technologies has a net margin of 7.85% compared to Prothena's net margin of -98.86%. Dynavax Technologies' return on equity of 3.19% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Dynavax Technologies7.85% 3.19% 2.02% Prothena -98.86%-24.03%-20.12% SummaryDynavax Technologies beats Prothena on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. Get Dynavax Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DVAX vs. The Competition Export to ExcelMetricDynavax TechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.76B$7.04B$5.38B$8.88BDividend YieldN/A8.03%4.99%4.03%P/E Ratio103.0111.49127.4917.46Price / Sales7.58348.331,259.5193.02Price / CashN/A49.2239.4136.42Price / Book2.589.096.295.86Net Income-$6.39M$154.47M$119.70M$225.23M7 Day Performance11.40%-2.22%-1.07%-0.88%1 Month Performance28.01%7.49%3.64%3.72%1 Year Performance-2.97%37.73%36.57%26.42% Dynavax Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DVAXDynavax Technologies4.6574 of 5 stars$13.39-1.0%$22.00+64.3%-0.2%$1.76B$232.28M103.01408Short Interest ↑Analyst RevisionPRTAProthena1.7368 of 5 stars$18.08+2.1%N/A-48.2%$972.34M$91.37M-18.08173Earnings ReportAnalyst ForecastNews CoverageGap UpRIGLRigel Pharmaceuticals3.1692 of 5 stars$24.95+13.0%N/A+242.2%$438.87M$116.88M178.23147Analyst ForecastNews CoverageHigh Trading VolumeGTHXG1 Therapeutics0.3805 of 5 stars$7.15flatN/AN/A$373.81M$58.20M-11.53170URGNUroGen Pharma3.9897 of 5 stars$12.79+5.5%N/A+3.4%$299.93M$82.71M-4.06200Analyst RevisionPBYIPuma Biotechnology3.7419 of 5 stars$3.30+14.6%N/A-21.8%$161.87M$235.60M6.88185Earnings ReportAnalyst UpgradeHigh Trading VolumeIONSIonis Pharmaceuticals4.1241 of 5 stars$38.88-0.8%N/A-19.7%$6.14B$788M-15.93800Analyst DowngradeInsider SellingShort Interest ↑Analyst RevisionALKSAlkermes4.3933 of 5 stars$30.08+4.2%N/A+21.9%$4.67B$1.51B15.422,100Analyst ForecastInsider SellingFOLDAmicus Therapeutics4.6167 of 5 stars$10.69-2.7%N/A+1.0%$3.19B$399.36M-31.44480Analyst ForecastShort Interest ↓GERNGeron3.536 of 5 stars$4.12-3.1%N/A+115.0%$2.48B$240,000.00-12.88141Earnings ReportAnalyst RevisionLGNDLigand Pharmaceuticals4.9932 of 5 stars$123.47+1.8%N/A+121.3%$2.26B$131.31M49.1980Analyst Forecast Related Companies and Tools Related Companies PRTA Competitors RIGL Competitors GTHX Competitors URGN Competitors PBYI Competitors IONS Competitors ALKS Competitors FOLD Competitors GERN Competitors LGND Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DVAX) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DVAX Stock Alerts